GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rain Oncology Inc (NAS:RAIN) » Definitions » Cash Flow from Investing

Rain Oncology (Rain Oncology) Cash Flow from Investing : $10.15 Mil (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Rain Oncology Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2023, Rain Oncology spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $12.89 Mil on purchasing investments. It gained $19.50 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $2.38 Mil for other investing activities. In all, Rain Oncology gained $4.24 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2023.


Rain Oncology Cash Flow from Investing Historical Data

The historical data trend for Rain Oncology's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rain Oncology Cash Flow from Investing Chart

Rain Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Cash Flow from Investing
-0.14 -5.19 -118.24 47.19

Rain Oncology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.63 -17.19 3.52 19.59 4.24

Rain Oncology Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Rain Oncology's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:

Rain Oncology's Cash Flow from Investing for the quarter that ended in Sep. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rain Oncology  (NAS:RAIN) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Rain Oncology's purchase of property, plant, equipment for the three months ended in Sep. 2023 was $0.00 Mil. It means Rain Oncology spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Rain Oncology's sale of property, plant, equipment for the three months ended in Sep. 2023 was $0.00 Mil. It means Rain Oncology gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Rain Oncology's purchase of business for the three months ended in Sep. 2023 was $0.00 Mil. It means Rain Oncology spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Rain Oncology's sale of business for the three months ended in Sep. 2023 was $0.00 Mil. It means Rain Oncology gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Rain Oncology's purchase of investment for the three months ended in Sep. 2023 was $-12.89 Mil. It means Rain Oncology spent {stock_data.stock.currency_symbol}}12.89 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Rain Oncology's sale of investment for the three months ended in Sep. 2023 was $19.50 Mil. It means Rain Oncology gained $19.50 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Rain Oncology's net Intangibles purchase and sale for the three months ended in Sep. 2023 was $0.00 Mil. It means Rain Oncology paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Rain Oncology's cash from discontinued investing activities for the three months ended in Sep. 2023 was 0.00 Mil. It means Rain Oncology paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Rain Oncology's cash from other investing activities for the three months ended in Sep. 2023 was $-2.38 Mil. It means Rain Oncology paid $2.38 Mil for other investing activities.


Rain Oncology Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Rain Oncology's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Rain Oncology (Rain Oncology) Business Description

Traded in Other Exchanges
N/A
Address
8000 Jarvis Avenue, Suite 204, Newark, CA, USA, 94560
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Executives
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Josephine Bruce officer: Principal Fin. & Acc. Officer 8000 JARVIS AVENUE, SUITE 204, NEWARK CA 94560
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Boxer Capital, Llc other: See remarks. 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis other: See remarks. PO BOX N7776, LYFORD BAHAMAS
Aaron I. Davis director 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Erik Atkisson officer: General Counsel and CCO C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Avanish Vellanki director, officer: President and CEO 8000 JARVIS AVENUE, SUITE 204, NEWARK CA 94560
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Gorjan Hrustanovic director C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472

Rain Oncology (Rain Oncology) Headlines

From GuruFocus